| Prev Close | 228.97 |
| Open | 228.10 |
| Day Low/High | 226.16 / 229.93 |
| 52 Wk Low/High | 177.05 / 264.97 |
| Volume | 2.17M |
Amgen Inc. (AMGN)
227.79
1.20
0.52
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 585.69B |
| Market Cap | 135.35B |
| P/E Ratio | 18.87 |
| Div & Yield | N.A. (N.A) |
Latest News
No Ordinary Month, Fear September?, Put/Call Ratio, TikTok Bidding War, Amazon
How September markets digest August ahead of momentous events will be far more important to uptrend maintenance than how August closed.
Pizza, Splits and Stocks
Apple's weight in the (price-weighted) Dow Jones Industrial Average, effective this morning, will be reduced from 12% to 3% -- based on the company's 4-1 stock split. In response to that split, Amgen , Honeywell , and Salesforce are being added to t...
Weakness in September? Dwindling Trading Volume, Fed Speak, Cybersecurity Stocks
September, not October, is historically the weakest month of the year for equity markets, though October has had more high profile collapses.
A Healthy Dose of Vaccine and Pharmaceutical Plays
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Amgen Might Be the Right Medicine for the Dow
Let's check the charts as this biotech replaces Pfizer on the DJIA.
Jim Cramer: All These Stocks Are Not Quite 'Dow and Out'
Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Here's Something to Try if You're Looking to Get Long Honeywell
What I see: This stock responds well to economic recovery.
Apple Still King, Dow Shell Game, More Market Faith, Renewed China Talks?
Monday's market action was in no way similar to that recent disparity between the 'haves' and 'have nots.'
Danger Beneath the Waves, Chip Stocks Ahoy, Fiscal Battle, Sizing Up Starbucks
Negotiations on the next round of stimulus, more so than tension between Washington and Beijing, and more so than earnings season, will control short-term financial market performance.
SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities
I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.
Regeneron, PayPal, Facebook Push Up Real Money Post Industrial Average
The RMPIA rose 3.2% for May and 3.3% for the first five months of 2020.
Buffett's Great Airline Escape, Tech Leadership, ECB Wiggle Room
Don't just follow the herd, time your exits and entrances well -- even if it is a big player like Warren Buffett that is leading the charge.
Trading Volumes Rising, GDP Forecasts, Earnings and Trading Thoughts
Market leadership may be lacking on Thursday despite rising trading volumes, plus an update on Apple, Microsoft, Mastercard, Amazon and Gilead.
Amgen Looks Set to Soar to New Heights - Despite the Naysayers
Here's how to play the biotech with earnings on the horizon.
The Market Refuses to Embrace Negatives as Major Earnings Reports Roll In
So far, earnings season has not been the obstacle that many have feared.
Jim Cramer: Here Are the Stocks That 'Transom' Money Is Buying
They buy and buy and buy. The same stocks. Over and over. No end to it.
Real Money Post Industrial Average Leads, but Coronavirus Adds Uncertainty
RMPIA ended January up 0.8%, but now the damage from the Wuhan virus is weighing on the future.
The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon
It's no secret that the Fed would like to get out of the short-term repo business.
Market Prices in New Risk, Action for 9 Stocks in My Portfolio: Market Recon
What I suggest individual investors do is give their portfolios a physical. Like a visit to the doctor.
My Pick for 2020? You Won't Believe It's Been on Your Screen All Along
This company made headlines in 2019, and I'm betting on it as a great play -- in many senses of the word -- for this new year.
3 Boomer-Inspired Drug Plays With Dividend Appeal
Bristol-Myers Squibb, Amgen and Abbott Labs all recently raised their dividends and should prosper amid the aging population.
Amgen Gets Shot in the Arm, Could Bounce Up in Months Ahead
AMGN appears to have taken a turn for the better and is now looking at targets of $254 and $270.
RMPIA Lags in November, but Trounces S&P 500 for Quarter, Year So Far
Now, many Real Money Post Industrial Average stocks should see a boost from the holiday splurge by shoppers.
News While You Slept, Semi Tough and Updates on Amgen and Splunk: Market Recon
Also, Fed Chairman Powell says there are no plans for a U.S. digital currency (for now), plus Tesla's electric pickup.
Real Money Post Industrial Average Exits October on Top
The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.
